S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
France backs Italy in vaccine ban as EU defends mechanism
pixel
3 Tech Stocks on Sale to Buy Carefully
Analysts are Calling These 3 Pullbacks Buy Opportunities
China sets growth target 'over 6%,' tightening HK control
SEC suing AT&T for telling analysts nonpublic information
Tech rebound pulls stocks out of a slump and to weekly gain
US stocks turn mixed as bond yields continue their climb
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
France backs Italy in vaccine ban as EU defends mechanism
pixel
3 Tech Stocks on Sale to Buy Carefully
Analysts are Calling These 3 Pullbacks Buy Opportunities
China sets growth target 'over 6%,' tightening HK control
SEC suing AT&T for telling analysts nonpublic information
Tech rebound pulls stocks out of a slump and to weekly gain
US stocks turn mixed as bond yields continue their climb
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
France backs Italy in vaccine ban as EU defends mechanism
pixel
3 Tech Stocks on Sale to Buy Carefully
Analysts are Calling These 3 Pullbacks Buy Opportunities
China sets growth target 'over 6%,' tightening HK control
SEC suing AT&T for telling analysts nonpublic information
Tech rebound pulls stocks out of a slump and to weekly gain
US stocks turn mixed as bond yields continue their climb
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
France backs Italy in vaccine ban as EU defends mechanism
pixel
3 Tech Stocks on Sale to Buy Carefully
Analysts are Calling These 3 Pullbacks Buy Opportunities
China sets growth target 'over 6%,' tightening HK control
SEC suing AT&T for telling analysts nonpublic information
Tech rebound pulls stocks out of a slump and to weekly gain
US stocks turn mixed as bond yields continue their climb
Log in
NASDAQ:RUBY

Rubius Therapeutics Earnings Date, Estimates & History

$12.56
+2.16 (+20.77 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.09
Now: $12.56▼
$15.18
50-Day Range
$8.02
MA: $11.48▼
$14.93
52-Week Range
$3.35
Now: $12.56▼
$15.99
Volume2.99 million shs
Average Volume761,768 shs
Market Capitalization$1.02 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.37

Earnings

Rubius Therapeutics (NASDAQ:RUBY) Earnings Information

Rubius Therapeutics last released its quarterly earnings results on February 23rd, 2021. The reported ($0.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.03. Rubius Therapeutics has generated ($2.08) earnings per share over the last year. Rubius Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 10th, 2021 based off prior year's report dates.

Rubius Therapeutics Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Rubius Therapeutics (NASDAQ:RUBY) Earnings Estimates

2021 EPS Consensus Estimate: ($2.00)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20212($0.59)($0.49)($0.54)
Q2 20212($0.57)($0.37)($0.47)
Q3 20212($0.58)($0.39)($0.49)
Q4 20212($0.60)($0.41)($0.51)

Rubius Therapeutics (NASDAQ RUBY) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSGAAP EPSRevenue EstimateActual RevenueConference CallDetails
5/10/2021
(Estimated)		       
2/23/202112/31/2020($0.53)($0.50)($0.50)N/A
11/9/20209/30/2020($0.50)($0.51)($0.51)Listen
8/10/20206/30/2020($0.50)($0.47)($0.47)N/A
5/11/20203/31/2020($0.56)($0.60)($0.60)Transcript
3/12/202012/31/2019($0.60)($0.56)($0.56)Transcript
11/14/2019Q3($0.53)($0.59)($0.59)N/A
8/13/2019Q2 2019($0.46)($0.50)($0.50)N/A
5/15/20193/31/2019($0.38)($0.42)($0.42)N/A
3/28/201912/31/2018($0.42)($0.35)($0.35)N/A
11/13/2018Q3 2018($0.36)($0.42)($0.42)N/A
8/31/2018Q2 2018($0.60)($3.33)($3.33)N/A
(Earnings results data provided by Zacks Investment Research)
This page was last updated on 3/6/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.